Breast cancer odds ratios (95% confidence intervals) by genotype
Genotype . | n* . | Odds ratio† (95% confidence interval) . | Odds ratio‡ (95% confidence interval) . | |||
---|---|---|---|---|---|---|
CYP1A1*2A | ||||||
TT | 743/722 | 1.0 | 1.0 | |||
TC | 493/530 | 1.0 (0.9-1.2) | 1.0 (0.8-1.2) | |||
CC | 103/118 | 1.0 (0.8-1.4) | 1.0 (0.6-1.4) | |||
P | 0.78§ | 0.85 | ||||
CYP1A2*1F | ||||||
AA | 640/617 | 1.0 | 1.0 | |||
AC | 608/627 | 0.9 (0.7-1.0) | 0.9 (0.7-1.0) | |||
CC | 91/125 | 0.8 (0.6-1.0) | 0.7 (0.5-1.0) | |||
P | 0.03 | 0.03 | ||||
CYP1B1 Leu432Val | ||||||
LL | 581/516 | 1.0 | 1.0 | |||
LV | 495/525 | 1.0 (0.8-1.1) | 0.9 (0.8-1.1) | |||
VV | 263/329 | 0.9 (0.7-1.2) | 0.9 (0.7-1.1) | |||
P | 0.47 | 0.32 | ||||
AHR Arg554Lys | ||||||
RR | 721/756 | 1.0 | 1.0 | |||
RL | 463/456 | 1.1 (0.9-1.3) | 1.1 (0.9-1.3) | |||
LL | 155/158 | 1.0 (0.8-1.3) | 1.0 (0.7-1.3) | |||
P | 0.62 | 0.75 | ||||
CYP3A4*1B | ||||||
AA | 1,080/994 | 1.0 | 1.0 | |||
AG | 164/254 | 0.9 (0.7-1.2) | 0.9 (0.7-1.2) | |||
GG | 95/122 | 1.1 (0.6-1.6) | 1.1 (0.8-1.7) | |||
P | 0.66 | 0.68 | ||||
COMT Val158Met | ||||||
Val/Val | 519/550 | 1.0 | 1.0 | |||
Val/Met | 624/614 | 1.0 (0.9-1.2) | 1.0 (0.8-1.2) | |||
Met/Met | 196/206 | 0.9 (0.7-1.2) | 0.9 (0.7-1.2) | |||
P | 0.71 | 0.64 | ||||
SULT1A1 Arg213His | ||||||
Arg/Arg | 801/782 | 1.0 | 1.0 | |||
Arg/His | 424/484 | 0.9 (0.7-1.0) | 0.9 (0.7-1.0) | |||
His/His | 114/104 | 1.1 (0.8-1.5) | 1.1 (0.8-1.5) | |||
P | 0.63 | 0.63 |
Genotype . | n* . | Odds ratio† (95% confidence interval) . | Odds ratio‡ (95% confidence interval) . | |||
---|---|---|---|---|---|---|
CYP1A1*2A | ||||||
TT | 743/722 | 1.0 | 1.0 | |||
TC | 493/530 | 1.0 (0.9-1.2) | 1.0 (0.8-1.2) | |||
CC | 103/118 | 1.0 (0.8-1.4) | 1.0 (0.6-1.4) | |||
P | 0.78§ | 0.85 | ||||
CYP1A2*1F | ||||||
AA | 640/617 | 1.0 | 1.0 | |||
AC | 608/627 | 0.9 (0.7-1.0) | 0.9 (0.7-1.0) | |||
CC | 91/125 | 0.8 (0.6-1.0) | 0.7 (0.5-1.0) | |||
P | 0.03 | 0.03 | ||||
CYP1B1 Leu432Val | ||||||
LL | 581/516 | 1.0 | 1.0 | |||
LV | 495/525 | 1.0 (0.8-1.1) | 0.9 (0.8-1.1) | |||
VV | 263/329 | 0.9 (0.7-1.2) | 0.9 (0.7-1.1) | |||
P | 0.47 | 0.32 | ||||
AHR Arg554Lys | ||||||
RR | 721/756 | 1.0 | 1.0 | |||
RL | 463/456 | 1.1 (0.9-1.3) | 1.1 (0.9-1.3) | |||
LL | 155/158 | 1.0 (0.8-1.3) | 1.0 (0.7-1.3) | |||
P | 0.62 | 0.75 | ||||
CYP3A4*1B | ||||||
AA | 1,080/994 | 1.0 | 1.0 | |||
AG | 164/254 | 0.9 (0.7-1.2) | 0.9 (0.7-1.2) | |||
GG | 95/122 | 1.1 (0.6-1.6) | 1.1 (0.8-1.7) | |||
P | 0.66 | 0.68 | ||||
COMT Val158Met | ||||||
Val/Val | 519/550 | 1.0 | 1.0 | |||
Val/Met | 624/614 | 1.0 (0.9-1.2) | 1.0 (0.8-1.2) | |||
Met/Met | 196/206 | 0.9 (0.7-1.2) | 0.9 (0.7-1.2) | |||
P | 0.71 | 0.64 | ||||
SULT1A1 Arg213His | ||||||
Arg/Arg | 801/782 | 1.0 | 1.0 | |||
Arg/His | 424/484 | 0.9 (0.7-1.0) | 0.9 (0.7-1.0) | |||
His/His | 114/104 | 1.1 (0.8-1.5) | 1.1 (0.8-1.5) | |||
P | 0.63 | 0.63 |